Startseite
Kongressberichte 2020
ASCO20 Virtual Scientific Meeting
Studies presented at press briefings
Pre-Meeting Presentation
Pre-Conference Press Briefing
Andres Poveda, Anne Floquet, Jonathan A. Ledermann, et al.
The abstract concludes:
"In the final analysis of SOLO2, maintenance olaparib provided an unprecedented improvement of 12.9 months in median OS vs placebo. This is the first study with olaparib tablets, and the first since Study 19 (NCT00753545), to provide long-term follow-up and final OS data in pts with PSROC and a BRCAm. Clinical trial information: NCT01874353" (Note the table in the abstract)
View the press briefing presentation
--------------------------------------------------------------------------------------------------------------------------------------------------------
Aline Fusco Fares, Mei Jiang, Ping Yang, et al.
The abstract concludes:
"Among ex-smokers, the risk of overall death was reduced by 12% on < 2y TSSC, 17% on 2-5y TSSC and 20% > 5y TSSC, whereas for LCSS, the benefit was significant only for > 5y TSCC, compared to current smokers at time of diagnosis. Here we demonstrate that convincing screening participants to quit smoking at any point of their trajectory, even just prior to dx such as < 2y TSSC, improved OS, and LCSS benefit was present beyond 5y of quitting. These relationships are independent of pack-years, age, across all stages and other prognostic variables."
View the press briefing presentation
--------------------------------------------------------------------------------------------------------------------------------------------------------
Sara L Douglas, Polly Mazanec, Amy R Lipson, et al.
The abstract concludes:
"These data suggest that the use of a coaching videoconference intervention made significant and clinically meaningful differences in anxiety and distress for these important members of the family caregiving team. Clinical trial information: NCT02666183."
View the press briefing presentation
--------------------------------------------------------------------------------------------------------------------------------------------------------
Wee-Kheng Soo, Madeleine King, Alun Pope, et al.
The abstract concludes:
"Integrated oncogeriatric care led to improvements in HRQOL, unplanned hospital admissions and treatment discontinuation in older people receiving systemic anti-cancer therapy. Older people (>70 years) planned for anti-cancer therapy should receive CGAM to optimize their clinical care and health outcomes. Clinical trial information: ACTRN12614000399695."